Zipline selected as 2019 Red Herring Top 100 North America Winner

ZipLine Medical, Inc. was selected as a winner of the Red Herring Top 100 North America award, which recognizes the continent's most exciting and innovative private technology companies.

Winners were chosen from thousands of entrants in a gamut of verticals, from financial technology to marketing, and medical devices to Internet of things. Companies were judged by industry experts, insiders and journalists on a wide variety of criteria, including financial performance, innovation, business strategy, and market penetration. Red Herring’s editors have been evaluating the world’s startups and tech companies for over two decades and their insights enable them to select firms that will continue on a trajectory to success. Brands such as Alibaba, Google, Kakao, Skype, Spotify, Twitter and YouTube have all been singled out as Red Herring winners in the past.

The Zip® Surgical Skin Closure and PreLoc Wound Closure devices have seen significant adoption in key surgical procedures such as total joint replacement and limb salvage. In addition to the economic benefits these devices provide to the hospital and clinic, the high degree of patient satisfaction they engender has created word of mouth that often drives a patient’s friends and family to request ZipLine devices for their next surgery.

"Adoption of the Zip device in our procedures represents the cutting edge of surgery. Orthopedic patients are becoming more and more educated on the products and techniques that offer the best surgical outcomes, and come to the table expecting these from their surgeon," said Robert C. Marchand MD, orthopedic surgeon and robotic joint replacement expert in Wakefield, Rhode Island. "The Zip enables us to provide patients with a more comfortable recovery and better cosmetic outcome while reducing surgical procedure time and patient complications that add costs to the healthcare system.

ZipLine Medical, Inc.

ZipLine Medical, Inc.
Post-surgical wound closure devices

Downloads

DownloadPress Release

Latest News

MVM invests in MDxHealth SA

MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.

MVM leads investment round in SkyCell

MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.

Valneva and Pfizer announce collaboration on Lyme Disease vaccine, VLA-15

Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

MVM Partners LLP Closes Fund V

MVM Partners announces the closing of a $325 million healthcare fund, MVM V.

HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events

HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.

Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test

Biotheranostics announces the launch of its Not Another minute campaign, revealing how Breast Cancer Index is changing the game for early-stage, hormone receptor-positive breast cancer patients.